Fig. 7
From: Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
mIL-21 enhanced the anti-tumor activity of mNKG2D CAR-NK cells. (A) Schematic representation of mNKG2D (n = 5). (B) Flow cytometry analysis of the transfection efficiencies. (C) qRT-PCR analysis of IL-21 mRNA level in NK, mNKG2D CAR-NK, and mNKG2D-IL-21 CAR-NK cells. (D) Rae-1 expression of lung cancer cell line was detected by flow cytometry. (E) Line plots of the cytotoxicities of mNK, mNKG2D CAR-NK, and mNKG2D-IL-21 CAR-NK cells against the lung cancer cell line at a different effector to target (E: T) ratios for 4 h. (F-G) Tumor images of mice injected with A549 cells at the indicated time points. (H) Histogram of the weights of tumors. (I) Immunofluorescent staining revealed the expression of CD3 and NK1.1. Cell nuclei are stained with DAPI. Data were representative of three independent experiments. ** P < 0.01; *** P < 0.001